CytomX Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
CytomX Therapeutics, Inc. (CTMX) reported Revenue from Contract with Customer, Excluding Assessed Tax of $1.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- CytomX Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $1.42M, a 92.40% decline year-over-year.
- CytomX Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $10.26M, a 79.85% decline year-over-year.
- CytomX Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $663.00K, a 98.26% decline year-over-year.
- CytomX Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $5.96M, a 82.16% decline year-over-year.
- CytomX Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $76.20M, a 44.82% decline from fiscal 2024.
- CytomX Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $138.10M, a 36.45% increase from fiscal 2023.
- CytomX Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $101.21M, a 90.38% increase from fiscal 2022.
- CytomX Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $53.16M, a 42.48% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.42M 10-Q · filed 2026-08-06 | $11.68M 10-Q · filed 2026-08-06 | $12.34M derived: sum of 3 quarters · filed 2026-08-06 | $18.30M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $10.26M 10-Q · filed 2026-05-07 | $10.92M derived: sum of 2 quarters · filed 2026-05-07 | $16.88M derived: sum of 3 quarters · filed 2026-05-07 | $35.54M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $663.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $6.63M derived: sum of 2 quarters · filed 2026-03-16 | $25.28M derived: sum of 3 quarters · filed 2026-08-06 | $76.20M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | $5.96M 10-Q · filed 2025-11-06 | $24.62M derived: sum of 2 quarters · filed 2026-08-06 | $75.54M 10-Q · filed 2025-11-06 | $113.63M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $18.66M 10-Q · filed 2026-08-06 | $69.58M 10-Q · filed 2026-08-06 | $107.67M derived: sum of 3 quarters · filed 2026-08-06 | $141.10M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $50.92M 10-Q · filed 2026-05-07 | $89.01M derived: sum of 2 quarters · filed 2026-05-07 | $122.44M derived: sum of 3 quarters · filed 2026-05-07 | $147.56M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $38.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $71.53M derived: sum of 2 quarters · filed 2026-03-16 | $96.64M derived: sum of 3 quarters · filed 2026-03-16 | $138.10M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $33.43M 10-Q · filed 2025-11-06 | $58.55M derived: sum of 2 quarters · filed 2025-11-06 | $100.01M 10-Q · filed 2025-11-06 | $126.62M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $25.11M 10-Q · filed 2025-08-07 | $66.58M 10-Q · filed 2025-08-07 | $93.19M derived: sum of 3 quarters · filed 2025-08-07 | $119.57M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $41.46M 10-Q · filed 2025-05-12 | $68.07M derived: sum of 2 quarters · filed 2025-05-12 | $94.45M derived: sum of 3 quarters · filed 2025-05-12 | $119.18M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $26.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $52.99M derived: sum of 2 quarters · filed 2025-03-06 | $77.72M derived: sum of 3 quarters · filed 2025-03-06 | $101.21M 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $26.38M 10-Q · filed 2024-11-07 | $51.11M derived: sum of 2 quarters · filed 2024-11-07 | $74.61M 10-Q · filed 2024-11-07 | $94.73M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $24.72M 10-Q · filed 2024-08-08 | $48.22M 10-Q · filed 2024-08-08 | $68.35M derived: sum of 3 quarters · filed 2024-08-08 | $79.49M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $23.50M 10-Q · filed 2024-05-08 | $43.62M derived: sum of 2 quarters · filed 2024-05-08 | $54.77M derived: sum of 3 quarters · filed 2024-05-08 | $67.62M derived: sum of 4 quarters · filed 2024-05-08 | ||||
| 2022-12-31 | $20.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $31.27M derived: sum of 2 quarters · filed 2024-03-11 | $44.12M derived: sum of 3 quarters · filed 2024-03-11 | $53.16M 10-K · filed 2024-03-11 | ||||
| 2022-09-30 | $11.15M 10-Q · filed 2023-11-07 | $16.91M 10-Q · filed 2022-11-08 | $24.00M derived: sum of 2 quarters · filed 2023-11-07 | $33.04M 10-Q · filed 2023-11-07 | $52.22M 10-Q · filed 2022-11-08 | $44.17M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $12.85M 10-Q · filed 2023-08-08 | $18.16M 10-Q · filed 2022-08-04 | $21.89M 10-Q · filed 2023-08-08 | $35.30M 10-Q · filed 2022-08-04 | $33.02M derived: sum of 3 quarters · filed 2023-08-08 | $42.21M derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | $9.04M 10-Q · filed 2023-05-09 | $17.14M 10-Q · filed 2022-05-05 | $20.17M derived: sum of 2 quarters · filed 2023-05-09 | $29.36M derived: sum of 3 quarters · filed 2023-05-09 | $38.16M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $11.13M 10-K/A · filed 2023-03-27 | $20.32M derived: sum of 2 quarters · filed 2023-03-27 | $29.12M derived: sum of 3 quarters · filed 2023-03-27 | $37.31M 10-K/A · filed 2023-03-27 | $69.57M 10-K · filed 2022-03-01 | |||
| 2021-09-30 | $9.19M 10-K/A · filed 2023-03-27 | $17.59M 10-Q · filed 2021-11-04 | $17.98M derived: sum of 2 quarters · filed 2023-03-27 | $26.18M 10-K/A · filed 2023-03-27 | $49.85M 10-Q · filed 2021-11-04 | $33.26M derived: sum of 4 quarters · filed 2023-03-27 | ||
| 2021-06-30 | $8.79M 10-K/A · filed 2023-03-27 | $16.29M 10-Q · filed 2021-08-05 | $16.99M 10-K/A · filed 2023-03-27 | $32.26M 10-Q · filed 2021-08-05 | $24.07M derived: sum of 3 quarters · filed 2023-03-27 | $31.54M derived: sum of 4 quarters · filed 2023-03-27 | ||
| 2021-03-31 | $8.20M 10-K/A · filed 2023-03-27 | $15.97M 10-Q · filed 2021-05-06 | $15.28M derived: sum of 2 quarters · filed 2023-03-27 | $22.74M derived: sum of 3 quarters · filed 2023-03-27 | $29.73M derived: sum of 4 quarters · filed 2023-03-27 | |||
| 2020-12-31 | $7.08M 10-K/A · filed 2023-03-27 | $14.54M derived: sum of 2 quarters · filed 2023-03-27 | $21.53M derived: sum of 3 quarters · filed 2023-03-27 | $68.43M 10-K/A · filed 2023-03-27 | $100.36M 10-K · filed 2021-02-24 | |||
| 2020-09-30 | $7.47M 10-K/A · filed 2023-03-27 | $17.79M 10-Q · filed 2020-11-05 | $14.45M derived: sum of 2 quarters · filed 2023-03-27 | $61.35M 10-K/A · filed 2023-03-27 | $83.99M 10-Q · filed 2020-11-05 | $69.63M derived: sum of 4 quarters · filed 2023-03-27 | ||
| 2020-06-30 | $6.99M 10-K/A · filed 2023-03-27 | $16.61M 10-Q · filed 2020-08-06 | $53.88M 10-K/A · filed 2023-03-27 | $66.20M 10-Q · filed 2020-08-06 | $62.16M derived: sum of 3 quarters · filed 2023-03-27 | $72.87M derived: sum of 4 quarters · filed 2023-03-27 | ||
| 2020-03-31 | $46.90M 10-K/A · filed 2023-03-27 | $49.59M 10-Q · filed 2020-05-07 | $55.17M derived: sum of 2 quarters · filed 2023-03-27 | $65.89M derived: sum of 3 quarters · filed 2023-03-27 | $74.90M derived: sum of 4 quarters · filed 2023-03-27 | |||
| 2019-12-31 | $8.28M 10-K · filed 2020-02-27 | $18.99M derived: sum of 2 quarters · filed 2020-11-05 | $28.00M derived: sum of 3 quarters · filed 2020-11-05 | $26.90M 10-K/A · filed 2023-03-27 | $57.49M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $10.71M 10-Q · filed 2020-11-05 | $19.73M derived: sum of 2 quarters · filed 2020-11-05 | $49.21M 10-Q · filed 2020-11-05 | $60.68M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $9.01M 10-Q · filed 2020-08-06 | $38.50M 10-Q · filed 2020-08-06 | $49.97M derived: sum of 3 quarters · filed 2020-08-06 | $62.48M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $29.48M 10-Q · filed 2020-05-07 | $40.96M derived: sum of 2 quarters · filed 2020-05-07 | $53.47M derived: sum of 3 quarters · filed 2020-05-07 | $74.80M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $11.47M 10-K · filed 2020-02-27 | $23.98M derived: sum of 2 quarters · filed 2020-02-27 | $45.32M derived: sum of 3 quarters · filed 2020-02-27 | $59.50M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $12.51M 10-K · filed 2020-02-27 | $33.85M derived: sum of 2 quarters · filed 2020-02-27 | $48.03M 10-Q · filed 2019-11-07 | $75.11M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $21.34M 10-K · filed 2020-02-27 | $35.52M 10-Q · filed 2019-08-07 | $62.60M derived: sum of 3 quarters · filed 2020-02-27 | $86.74M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $14.18M 10-K · filed 2020-02-27 | $41.26M derived: sum of 2 quarters · filed 2020-02-27 | $65.40M derived: sum of 3 quarters · filed 2020-02-27 | $74.15M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $27.07M 10-K · filed 2019-02-27 | $51.22M derived: sum of 2 quarters · filed 2019-02-27 | $59.97M derived: sum of 3 quarters · filed 2019-02-27 | $71.62M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $24.14M 10-K · filed 2019-02-27 | $32.90M derived: sum of 2 quarters · filed 2019-02-27 | $44.55M derived: sum of 3 quarters · filed 2019-02-27 | |||||
| 2017-06-30 | $8.75M 10-K · filed 2019-02-27 | $20.41M derived: sum of 2 quarters · filed 2019-02-27 | ||||||
| 2017-03-31 | $11.65M 10-K · filed 2019-02-27 | |||||||
| 2016-12-31 | $12.85M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |